Christopher Ryan Sullivan, CFO of Avalo Therapeutics AVTX, has filed 1 purchase and 12 sales on the open market. Over the past 12 months that comes to a net sale of $1.9M. The latest trade was on 06/10.

CS

CS

Christopher Ryan Sullivan

CFO

Company

Avalo Therapeutics AVTX

First filing

23/02/15

Trades

32 trades

Buys / sales

1 / 12

12-month net buying

−$1.9M

Last trade

06/10

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	05/07	05/11	18,606 sh	$24.12	$448,776.72	−97.8%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	05/06	05/07	47,000 sh5 trades	$20.18avg.	$948,605.89	−99.1%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	04/29–04/30	05/01	16,915 sh2 trades	$13.16avg.	$222,601.33	−97.6%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	04/01–04/02	04/03	15,959 sh4 trades	$16.96avg.	$270,600.17	−47.9%
Avalo TherapeuticsAVTX	Open-market buy	23/06/09	23/06/13	511 sh	$3.42	$1,747.62	+68.0%